Atovaquone

Generic name
Atovaquone
Brand name
ATC Code
P01AX06
Compare …

Atovaquone

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

T½ 2-3 days. Lipophilicity. Food increases the uptake by a factor of 2-3. Lower absorption in children younger than 2 years.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Prophylaxis for pneumonia caused by Pneumocystis jirovecii (PCP)
  • Oral
    • 1 month up to 3 months
      • 30 mg/kg/day in 1 dose
    • 3 months up to 2 years
      • 45 mg/kg/day in 1 dose
    • ≥ 2 years
      • 30 mg/kg/day in 1 dose. Max: 1.500 mg/day.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Hydroxyquinoline derivatives
P01AA02
Nitroimidazole derivatives
P01AB01

Reference

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor kinderen, 2007

Changes

Therapeutic Drug Monitoring


Overdose